Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET
Company Participants
Donald Notman - Chief Financial Officer
Antony Mattessich - President & Chief Executive Officer
Rabia Ozden - Chief Medical Officer
Steve Meyers - Senior Vice President of Commercial
Conference Call Participants
Jon Wolleben - JMP Securities
Joe Catanzaro - Piper Sandler
Tara Bancroft - Cowen
Colleen Kusy - Baird
Yi Chen - H.C. Wainwright
Caroline Palomeque - Berenberg Capital Markets
Operator
Good day, and thank you for standing by. Welcome to the Ocular Therapeutix First Quarter 2023 Earnings Conference Call. [Operator Instructions]. Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Donald Notman, Chief Financial Officer. Please go ahead.
Donald Notman
Thank you, Julia. Good afternoon, everyone, and thank you for joining us on our first quarter 2023 financial results and business update conference call. This afternoon, after the close, we issued a press release providing an update on the company's product development programs and details of the company's financial results for the first quarter ended March 31, 2023. The press release can be accessed on the Investors portion of our website at investors.ocutx.com.
Leading the call today will be Antony Mattessich, our President, and Chief Executive Officer, who will provide an update on our pipeline developments and the commercial progress of DEXTENZA. Also speaking on the call today will be Dr. Rabia Ozden, our Chief Medical Officer; and Steve Meyers, our Senior Vice President, Commercial.
Following their remarks, I will provide an overview of the financial highlights for the quarter before turning the call back over to Antony for a summary on questions. For Q&A, we will be joined by Chris White, our Chief Business Officer; and Dr. Peter Kaiser, our Chief Medical Adviser, Retina.
As a reminder, on today's call, certain statements we will be making may be considered forward-looking for the purposes of the Private Securities Litigation Reform Act of 1995. In particular, any statements regarding our regulatory and product development plans as well as our research activities are forward-looking statements. These statements are subject to a variety of risks and uncertainties that may cause actual results to differ from those forecasted, including those risks described in our Form 10-Q filed this afternoon with the SEC and our most recent annual report on Form 10-K filed March 6, 2023.